EVAX Latest Press Releases

-- October 23, 2026 --

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 Globe Newswire 2:00 AM

-- October 19, 2026 --

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 Globe Newswire 3:00 AM

-- October 2, 2026 --

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting Globe Newswire 9:00 AM

-- September 14, 2026 --

Evaxion applies its AI-Immunology platform in autoimmune diseases Globe Newswire 8:00 AM

-- August 20, 2026 --

Evaxion announces business update and second quarter 2026 financial results Globe Newswire 7:30 AM

-- August 17, 2026 --

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program Globe Newswire 8:00 AM

-- August 14, 2026 --

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 Globe Newswire 8:00 AM

-- July 17, 2026 --

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 Globe Newswire 7:15 AM

-- July 12, 2026 --

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 Globe Newswire 9:30 AM

-- July 1, 2026 --

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop Globe Newswire 8:00 AM

-- June 12, 2026 --

Evaxion receives Prix Galien UK Award for Best digital health solution Globe Newswire 3:00 AM

-- June 11, 2026 --

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia Globe Newswire 2:00 AM

Market Data Delayed 15 Minutes